

N-α-Fmoc-lysine (2)

N-α-Fmoc-Lys(N-ε-tBoc) (1)

Fig. 1a




Fig. 1b

Fig. 2a






Fig. 2b



sample 8320



sample 8242





Fig. 3a-1

sample 8243



sample 8318





Fig. 3a-2

sample 8320



sample 8326





Fig. 3b-1

sample 8242



sample 8243





Fig. 3b-2

sample 8243



sample 8318





Fig. 3c-1

sample 8326



sample 8242





Fig. 3c-2

HCV peptide II-BIO



HCV peptide XI-BIO




Fig. 4a

HCV peptide XVI-BIO






Fig. 4b

Fig. 5a



N-terminally biotinylated
TM peptide

Fig. 5b



C-terminally biotinylated
TM peptide

Fig. 6a-1





Fig. 6a-2





Fig. 6a-3





Fig. 6a-4





Fig. 6a-5





Fig. 6b-1





Fig. 6b-2





Fig. 6b-3





Fig. 6b-4





Fig. 6b-5





Fig. 6c-1





Fig. 6c-2





Fig. 6c-3





Fig. 6c-4





Fig. 6c-5





Fig. 6c-6





Fig. 6c-7





Fig. 6c-8





Fig. 6c-9





Fig. 6c-10





Fig. 7a-1

Peptide I	MSTIPKPQRKTKRNTNRRPQ	(SEQ ID NO:453)
peptide II	PQRKTKRNTNRRRPQDVKFPG	(SEQ ID NO:454)
peptide III	RNTNRRRPQDVKFPPGGGQIVG	(SEQ ID NO:455)


Peptide I	Peptide II	Peptide III
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(178) MSTIPKPQR	(184) PQRKTKRNT	(190) RNTNRRPQD
(179) STIPKPQRK	(185) QRKTKRNTN	(191) NTNRRRPQDV
(180) TIPKPQRKT	(186) RKTNRNTNR	(192) TNRRRPQDVK
(181) IPKPQRKTK	(187) KTKRNTNRR	(193) NRRPQDVKF
(182) PKPQRKTKR	(188) TKRNTNRRP	(194) RRPQDVKFPP
(183) KPQRKTKRN	(189) KRNTNRRPQ	(195) RPQDVKFPPG
(184) PQRKTKRNT	(190) RNTNRRRPQD	(196) PQDVKFPPGG
(185) QRKTKRNTN	(191) NTNRRRPQDV	(197) QDVKFPPGGG
(186) RKTNRNTNR	(192) TNRRRPQDVK	(198) DVKFPPGGGQ
(187) KTKRNTNRR	(193) NRRPQDVKF	(199) VKFPPGGGQI
(188) TKRNTNRRP	(194) RRPQDVKFPP	(200) KFPGGGQIV
(189) KRNTNRRPQ	(195) RPQDVKFPPG	(201) FPPGGGQIVG

Fig. 7a-2

Core 5 PGGGQIVGGVYLLPRRGPRL (SEQ ID NO:456)
 Peptide IV LPRRGPRRLGVRATRKTSERS (SEQ ID NO:457)
 Peptide V (SEQ ID NO:458) TRKTSERSQPRGRRQPIPKV
 Peptide VI (SEQ ID NO:459) RRQPIPKVRRPEGRTWAQPG

Core 5	Peptide IV	Peptide V	Peptides VI
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(202) PGGGQIVGG	(214) LPRRGPRRLG	TRKTSERSQ	(238) RRQPIPKVR
(203) GGGQIVGGV	(215) PRRGPRLGV	RKTSERSQP	(239) RQPIPKVRR
(204) GGQIVGGVY	(216) RRGPRRLGVR	KTSEERSQPR	(240) QPIPKVRRP
(205) GQIVGGVYL	(217) RGPRLGVRA	TSEERSQPRG	(241) PIPKVRRPE
(206) QIVGGVYLL	(218) GPRLGVRAT	SERSQPRGR	(242) IPKVRRPEG
(207) IVGGVYLLP	(219) PRLGVRATR	ERSQPRGRR	(243) PKVRRPEGR
(208) VGGVYLLPR	(220) RLGVRATR K	RSQPRGRRQ	(244) KVRRPEGRT
(209) GGVYLLPRR	(221) LGVRATRKT	SQPRGRRQP	(245) VRRPEGRTW
(210) GVYLLPRRG	(222) GVRATR KTS	QPRGRRQPI	(246) RRPEGRTWA
(211) VYLLPRRGP	(223) VRATRKTSE	PRGRRQPI P	(247) RPEGRTWAQ
(212) YLLPRRGPR	(224) RATRKTSE R	RGRRQPIPK	(248) PEGRTWAQP
(213) LLPRRGPR L	(225) ATRKTSERS	GRRQPIPKV	(249) EGRTWAQPG

Fig. 7a-3



Abstract

The diagram illustrates the experimental setup. A participant is seated at a table, looking at a video screen. A camera is positioned above the screen. A target is placed on the table. A horizontal arrow indicates the direction of movement from the starting point to the target. A vertical arrow indicates the direction of movement from the target to the starting point. A horizontal arrow indicates the direction of movement from the starting point to the target. A vertical arrow indicates the direction of movement from the target to the starting point.

<u>HCV1</u>	<u>HCV2</u>	<u>HCV3</u>	<u>HCV4</u>	<u>HCV5</u>	<u>HCV6</u>
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(258) LSGKPAIIP	264IIPDREVLY	270VLYREFDEM	276 DEMEECSQH	282SQHLPLYIEQ	288IEQGMMLAE
(259) SGKPAIIPD	265IIPDREVLYR	271LYREFDEME	277 EMEEC SQHL	283QHLPYIEQG	289EQGMMLAEQ
(260) GKPAIIPDR	266PDREVLYRE	272YREFDEME	278 MEECSQHLP	284HLPYIEQGM	290QGMMLAEQF
(261) KPAIIPDRE	267DREVLYREF	273REFDEME	279 EEC SQHLPY	285LPYIEQGM	291GMMLAEQFK
(262) PAIIPDREV	268 REVLYREFD	274EFDEME	280 ECSQHLPYI	286PYIEQGMML	292MMLAEQFKQ
(263) AIIPDREVL	269 EVLYREFDE	275FDEME	281 CSQHLPYIE	287YIEQGMMLA	293MLAEQFKQK
(264) IIPDREVLY	270 VLYREFDEM	276DEME	282 SQHLPLYIEQ	288IEQGMMLAE	294LAEQFKQKA
(265) IPDREVLYR	271 LYREFDEME	277EME	283 QHLPYIEQG	289EQGMMLAEQ	295AEQFKQKAL
(266) PDREVLYRE	272 YREFDEME	278ME	284 HLPYIEQGM	290QGMMLAEQF	296EQFKQKALG
(267) DREVLYREF	273 REFDEME	279EE	285 LPYIEQGM	291GMMLAEQFK	297QFKQKALGL
(268) REVLYREFD	274 EFDEME	280E	286 PYIEQGMML	292MMLAEQFKQ	298FKQKALGLL
(269) EVLYREFDE	275 FDEME	281C	287 YIEQGMMLA	293MLAEQFKQK	299KQKALGLLO

Fig. 7b-2

HCV7	LAEQFKQKALGLLQTASRQA (SEQ ID NO:466)
HCV8	QKALGLLQTASRQAEVIAPA (SEQ ID NO:467)
HCV9	LQTASRQAEVIAPAVQTNWQ (SEQ ID NO:468)

<u>HCV7</u>	<u>HCV8</u>	<u>HCV9</u>
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(294) LAEQFKQKA (300)	QKALGLLQT (306)	LQTASRQAE
(295) AEQFKQKAL (301)	KALGLLQTA (307)	QTASRQAEV
(296) EQFKQKALG (302)	ALGLLQTAS (308)	TASRQAEVI
(297) QFKQKALGL (303)	LGLLQTASR (309)	ASRQAEVIA
(298) FKQKALGLL (304)	GLLQTASRQ (310)	SRQAEVIAP
(299) KQKALGLLQ (305)	LLQTASRQA (311)	RQAEVIAPA
(300) QKALGLLQT (306)	LQTASRQAE (312)	QAEVIAPAV
(301) KALGLLQTA (307)	QTASRQAEV (313)	AEVIAPAVQ
(302) ALGLLQTAS (308)	TASRQAEVI (314)	EVIAPAVQT
(303) LGLLQTASR (309)	ASRQAEVIA (315)	VIAPAVQTN
(304) GLLQTASRQ (310)	SRQAEVIAP (316)	IAPAVQTNW
(305) LLQTASRQA (311)	RQAEVIAPA (317)	APAVQTNWQ

Fig. 7b-3



Fig. 7c-1

NS5-21 GNITRYESENKVVILDSFDP (SEQ ID NO:469)
 NS5-23 VILDSFDPLVAEEDEREISV (SEQ ID NO:470)
 NS5-25 EDEREISVPAEILRKSRFFA (SEQ ID NO:471)
 NS5-27 (SEQ ID NO:472) LRKSRFFAQLPVWARPDYN
 NS5-29 (SEQ ID NO:473) VWARPDYNPPLVETWKKPDY

	<u>NS5-21</u>	<u>NS5-23</u>	<u>NS5-25</u>	<u>NS5-27</u>	<u>NS5-29</u>
SEQ ID NO:	SEQ ID NO:	SEQ ID NO:	SEQ ID NO:	SEQ ID NO:	SEQ ID NO:
318	GNITRYESE 330	VILDSFDPL 342	EDEREISVP 354	LRKSRFFAQ 366	VWARPDYNP
319	NITRYESEN 331	ILDSFDPLV 343	DEREISVPA 355	RKSRFFAQ 367	WARPDYNPP
320	ITRYESENK 332	LDSFDPLVA 344	EREISVPAE 356	KSRFFAQAL 368	ARPDYNPPL
321	TRYESENKV 333	DSFDPLVAE 345	REISVPAEI 357	SRRFAQALP 369	RPDYNPPLV
322	RYESENKVV 334	SFDPLVAEE 346	EISVPAEIL 358	RRFAQALPV 370	PDYNPPLVE
323	YESENKVI 335	FDPLVAEED 347	ISVPAEILR 359	RFAQALPVW 371	DYNPPLVET
324	ESENKVVIL 336	DPLVAEED 348	SVPAEILRK 360	FAQALPVA 372	YNPPLVETW
325	SENKVVILD 337	PLVAEEDER 349	VPAEILRKS 361	AQALPVWAR 373	NPPLVETWK
326	ENKVVILDS 338	LVAEEDERE 350	PAEILRKSR 362	QALPVWARP 374	PPLVETWKK
327	NKVVILDSF 339	VAEEDEREI 351	AEILRKSR 363	ALPVWARPD 375	PLVETWKKP
328	KVVILDSFD 340	AEEDEREIS 352	EILRKSRFF 364	LPVWARPDY 376	LVETWKKPD
329	VVILDSFDP 341	EEEDEREISV 353	ILRKSRFFA 365	PVWARPDYN 377	VETWKKPDY

Fig. 7c-2

NS5-31
NS5-33

ETWKKPDYEPPVHGCPLPP (SEQ ID NO:474)
(SEQ ID NO:475) VHGCPLEPPKSPPPVPPRKK

<u>NS5-31</u>		<u>NS5-33</u>	
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
378	ETWKKPDYE	390	VHGCPLEPPK
379	TWKKPDYEP	391	HGCPLPPKS
380	WKKPDYEPP	392	GCPLPPKSP
381	KKPDYEPPV	393	CPLPPKSPP
382	KPDYEPPVV	394	PLPPKSPPV
383	PDYEPPVVH	395	LPPPKSPPV
384	DYEPPVVHG	396	PPKSPPVP
385	YEPVVHGC	397	PPKSPPVPP
386	EPPVVHGC	398	PKSPPVPPP
387	PPVVHGCPL	399	KSPVPPPPR
388	PVVHGCPLP	400	SPPVPPPRK
389	VVHGCPLPP	401	PPVPPPRKK

Fig. 7c-3




Fig. 7c-4





Fig. 8



- a: High intensity control
- b: Low intensity control
- c: Medium intensity control
- d: Peptide XXg-1, unbiotinylated
- e: Peptide XXg-2, unbiotinylated
- f: Biotinylated peptide XXg-1: streptavidin complex
- g: Biotinylated peptide XXg-2: streptavidin complex


[illegible]

Fig. 10




Fig. 11

Peptide	Sequence
NS4-a	GALVAFKIMSGEVPSTEDLV (SEQ ID NO:445)
NS4-b	VPSTEDLVNLLPAILSPGAL (SEQ ID NO:446)
NS4-c	AILSPGALVGVVCAAILRR (SEQ ID NO:447)
NS4-d	VCAAILRRHVGPGEQAVQWM (SEQ ID NO:448)
NS4-e	GEGAVQWMNRLIAFASRGNH (SEQ ID NO:449)

Fig. 12

(SEQ ID NO:)	Amino Acid Sequence
Epi-152 (450)	Bio- G G - I P D R E V L Y R G G K K P D Y E P P V G G R R P Q D V K F P <div data-bbox="584 1186 633 1543">NS4 epitope 1</div> <div data-bbox="584 756 633 1113">NS5 epitope 5</div> <div data-bbox="584 325 633 682">Core epitope 2</div>
Epi-33B3A (451)	Bio- G G - W A R P D Y N P P G G Q F K Q K A L G L G S G V Y L L P R R G <div data-bbox="706 1186 755 1543">NS5 epitope 3</div> <div data-bbox="706 756 755 1113">NS4 epitope 3B</div> <div data-bbox="706 325 755 682">Core epitope 3A</div>
Epi-4B2A6 (452)	Bio- G G - R G R R Q P I P K G G S Q H L P Y I E Q S G P V V H G C P L P <div data-bbox="828 1186 876 1543">Core epitope 4B</div> <div data-bbox="828 756 876 1113">NS4 epitope 2A</div> <div data-bbox="828 325 876 682">NS5 epitope 6</div>

	IgG control 3	IgG control 1	IgG control 2	Epi - 152	Epi - 33B3A	Epi - 4B2A6	Streptavidin control	Epi - 152	Epi - 33B3A	Epi - 4B2A6	Streptavidin control	carbonate buffer
8247	+											
8244	+			+	+							
8383	+			+	+	+		+				
8378	+			+	+	+		+				
8377	+			+	+			+	+			
8358	+			+	+			+	+			
8339	+			+	+	+		+	+	+		
8332	+			+	+			+	+			
8248	+			+	+	+		+	+	+		
8243	+			+	+			+	+			
8242	+			+	+	+		+				
8241	+			+	+			+	+			




Fig. 14c




Fig. 14d




Fig. 15




Fig. 16A





Fig. 16B

Cleavage and side-chain deprotection



Oxidation and dimerization




Fig. 17A





Fig. 17B



BBI ANTI-HTLV I/II MIXED TITER PERFORMANCE PANEL PRP302




Fig. 18

BLOOD DONOR SERA